Advertisement
Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (CUV.AX) Stock Competitors & Peer Comparison

See (CUV.AX) competitors and their performances in Stock Market.

CUV.AXASX
HealthcareBiotechnology
$10.25
$0.010(0.10%)
Australian Market opens in 50h 1m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CUV.AXA$10.26-0.19%525.3M16.17A$0.64+0.48%
CSL.AXA$117.75+2.62%56.7B12.73A$9.30+3.60%
TLX.AXA$17.18+3.62%5.8B-614.22-A$0.03N/A
MSB.AXA$2.05+4.86%2.6B-13.72-A$0.15N/A
NEU.AXA$17.00-4.23%2.2B75.14A$0.23N/A
PYC.AXA$1.62-3.86%979.5M-36.84-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
RAC.AXA$2.28+2.70%431.4M-106.28-A$0.02N/A
SPL.AXA$0.71+1.43%298.9M112.70A$0.01N/A
OCC.AXA$0.72-0.69%159.9M-26.67-A$0.03N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CUV.AX vs CSL.AX Comparison July 2026

CUV.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUV.AX stands at 525.3M. In comparison, CSL.AX has a market cap of 56.7B. Regarding current trading prices, CUV.AX is priced at A$10.26, while CSL.AX trades at A$117.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUV.AX currently has a P/E ratio of 16.17, whereas CSL.AX's P/E ratio is 12.73. In terms of profitability, CUV.AX's ROE is +0.13%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, CUV.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CUV.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions